Aligos Therapeutics, Inc. ( ALGS) - Key Metrics
ALGS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $2.66 | -$0.14 | -$2.39 | -$2.39 |
| 2026Q1 | $0.27 | -$2.21 | -$2.22 | -$2.23 |
| 2025Q4 | $0.02 | -$1.91 | -$2.09 | -$2.10 |
| 2025Q3 | $0.07 | -$3.04 | -$2.35 | -$2.37 |
| 2025Q2 | $0.09 | -$1.53 | -$1.50 | -$1.51 |
ALGS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -10.30 |
| 2026Q1 | 0% | -0.84 |
| 2025Q4 | 0% | -1.22 |
| 2025Q3 | 0% | -0.81 |
| 2025Q2 | 0% | -1.18 |
ALGS
Price: $6.76
52 week price:
Earnings Per Share: -7.43 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 78576
Market Capitalization: 43.7 million